27 June 2025 in Systemic Hypertension
Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver diseases. According to modern concepts, a unique feature of this pathology is that patients with NAFLD have a significantly increased risk of developing not only liver diseases, but also extrahepatic pathologies, mainly cardiovascular diseases (CVD). Various studies have clearly demonstrated the predictive role of NAFLD in the development of arterial hypertension, coronary heart disease, myocardial infarction, cardiac arrhythmias, and cardiovascular mortality. The commonality of pathogenetic mechanisms underlying NAFLD and CVD is discussed, primarily such as: dyslipidemia, hypertriglyceridemia, insulin resistance, lipotoxicity and chronic sterile inflammation. This review article analyzes the relationship between NAFLD and CVDs, describes the pathophysiological mechanisms of the bidirectional influence of these pathologies.
27 June 2025 in Systemic Hypertension
The aim of the study: to investigate the association of plasma resistin concentration with the vascular stiffness index CAVI and to identify factors associated with increased vascular stiffness in patients with arterial hypertension (AH).Materials and methods. 72 patients (34 men and 38 women) with AH aged 48 to 84 years were included in the study. Type 2 diabetes mellitus (T2DM) was diagnosed in 16 (22.2%) patients. Together with the standard investigations, all patients underwent determination of plasma resistin concentration and measurement of vascular stiffness based on the CAVI index.Results. All patients with AH were divided into 2 groups: patients with increased vascular stiffness (CAVI≥9) – 32 people (group 1) and patients with normal vascular stiffness (CAVI<9) – 40 people (group 2). A significantly higher concentration of resistin in blood plasma was observed in patients of group 1 – 6.23 [4.99; 8.35] ng/ml compared to group 2 – 4.1 [3.8; 5.58] ng/ml, p=0.036. Univariate linear regression analysis revealed a direct relationship between plasma resistin concentration and CAVI index (beta1=0.34; SD=0.08; p<0.001). According to multivariate regression analysis, independent markers of increased vascular stiffness in patients with AH were: age (OR=1.19, CI=1.06-1.30), T2DM (OR=2.39, CI=1.16-5.99), plasma resistin concentration (OR=1.46, CI=1.09-2.27), p<0.05. Resistin level more than 4.95 ng/ml with sensitivity of 65.2% and specificity of 56.5% allows to diagnose increased arterial stiffness in patients with AH (AUC=0.673, p<0.05).Conclusion. Independent markers of vascular stiffness in patients with AH are not only age and T2DM, but also a plasma resistin concentration of more than 4.95 ng/ml.
18 December 2024 in Consilium Medicum
Clinical observation is of interest due to the shift in the vector of the main complaints of the classic manifestation of Randu–Osler–Weber disease in the form of epistaxis and anemia syndrome towards the syndrome of severe respiratory failure, the cause of which is the presence of arteriovenous malformations in the lungs. The importance of an interdisciplinary approach to the diagnosis and treatment of patients with Randu–Osler–Weber disease is discussed.
29 October 2026 in Systemic Hypertension
Non-alcoholic fatty liver disease is one of the most common chronic liver diseases that has been proven to increase the risk of cardiovascular disease. The aim of the study: to study the characteristics of steatosis and liver fibrosis, as well as to analyze the body composition in patients with and without carbohydrate metabolism disorders and arterial hypertension (AH). Materials and methods . The study included 100 patients (31 men and 69 women) with AH aged 25 to 80 years with and without carbohydrate metabolism disorders. In addition to standard studies, all patients underwent determination of parameters of fatty hepatosis and liver fibrosis by transient elastometry (TE), determination of the compositional composition of the body. Liver steatosis was diagnosed according to the ultrasound attenuation parameter (UAP) of more than 244 dB/m, liver fibrosis was diagnosed according to the liver stiffness index Fs of more than 7.3 kPa. Results . The patients were divided into 3 groups: without carbohydrate metabolism disorders (50 people), with impaired glucose tolerance (IGT) (18 people), with type 2 diabetes mellitus (DM) (32 patients). The UAP value in patients with IGT significantly exceeded the value in patients without carbohydrate metabolism disorders. The Fs values in the groups with carbohydrate metabolism disorders were comparable, significantly exceeding the values in patients without carbohydrate metabolism disorders. In the group of patients with type 2 diabetes mellitus with non-target HbA1c, liver fibrosis was diagnosed in all examined. A direct correlation was found between the HbA1c level and the Fs indicator. Using linear regression analysis, it was found that an increase in HbA1c by 1% is associated with an increase in liver stiffness by 0.78 kPA. Conclusion . In patients with AH and IGT, the indicators of steatosis and liver stiffness were higher than in patients without carbohydrate metabolism disorders. The level of HbA1c is not only an indicator of carbohydrate metabolism, but also has predictive significance in relation to the development of liver fibrosis. Our study showed the need for a comprehensive examination of patients with carbohydrate metabolism disorders, including transient elastometry, for the timely diagnosis of steatosis and liver fibrosis.